| Literature DB >> 26759826 |
Arpita Basu1, Alicia J Jenkins2, Ying Zhang3, Julie A Stoner3, Richard L Klein4, Maria F Lopes-Virella4, W Timothy Garvey5, Timothy J Lyons6.
Abstract
Type 1 diabetes (T1DM) is associated with increased risk of macrovascular complications. We examined longitudinal associations of serum conventional lipids and nuclear magnetic resonance (NMR)-determined lipoprotein subclasses with carotid intima-media thickness (IMT) in adults with T1DM (n=455) enrolled in the Diabetes Control and Complications Trial (DCCT). Data on serum lipids and lipoproteins were collected at DCCT baseline (1983-89) and were correlated with common and internal carotid IMT determined by ultrasonography during the observational follow-up of the DCCT, the Epidemiology of Diabetes Interventions and Complications (EDIC) study, at EDIC 'Year 1' (199-1996) and EDIC 'Year 6' (1998-2000). This article contains data on the associations of DCCT baseline lipoprotein profiles (NMR-based VLDL & chylomicrons, IDL/LDL and HDL subclasses and 'conventional' total, LDL-, HDL-, non-HDL-cholesterol and triglycerides) with carotid IMT at EDIC Years 1 and 6, stratified by gender. The data are supplemental to our original research article describing detailed associations of DCCT baseline lipids and lipoprotein profiles with EDIC Year 12 carotid IMT (Basu et al. in press) [1].Entities:
Keywords: AER, Albumin Excretion Rate; BMI, Body Mass Index; CVD, CardioVascular Disease; Carotid intima-media thickness; DCCT, Diabetes Control and Complications Trial; EDIC, Epidemiology of Diabetes Interventions and Complications; IMT, Intima-Media Thickness; Lipids and lipoproteins; NMR-LSP, Nuclear Magnetic Resonance-determined Lipoprotein Subclass Profiles; T1DM, Type 1 Diabetes Mellitus.; Type 1 diabetes
Year: 2015 PMID: 26759826 PMCID: PMC4683326 DOI: 10.1016/j.dib.2015.11.036
Source DB: PubMed Journal: Data Brief ISSN: 2352-3409
DCCT baseline lipoprotein profiles vs. common carotid IMT-EDIC Years 1 and 6 (standardized linear regression coefficientsa).
| Variables | ||||||||
|---|---|---|---|---|---|---|---|---|
| Slope (SE) | Slope (SE) | Slope (SE) | Slope (SE) | |||||
| 0.02 (0.06) | 0.74 | −0.04 (0.05) | 0.42 | −0.05 (0.07) | 0.43 | −0.08 (0.07) | 0.22 | |
| Large VLDL and chylomicrons (nmol/L) | −0.12 (0.06) | −0.04 (0.05) | 0.48 | 0.01 (0.07) | 0.9 | −0.1 (0.07) | 0.14 | |
| Medium VLDL (nmol/L) | −0.13 (0.05) | −0.05 (0.05) | 0.35 | −0.04 (0.07) | 0.63 | −0.02 (0.08) | 0.78 | |
| Small VLDL (nmol/L) | 0.11 (0.06) | −0.02 (0.05) | 0.64 | −0.05 (0.06) | 0.43 | −0.08 (0.06) | 0.22 | |
| 0.12 (0.06) | 0.15 (0.05) | 0.12 (0.06) | 0.07 (0.07) | 0.33 | ||||
| IDL (nmol/L) | −0.06 (0.06) | 0.30 | −0.04 (0.05) | 0.42 | 0.06 (0.06) | 0.32 | 0.06 (0.06) | 0.36 |
| Large LDL (nmol/L) | 0.04 (0.06) | 0.48 | 0.06 (0.05) | 0.24 | 0.14 (0.06) | 0.04 (0.07) | 0.57 | |
| Small LDL (nmol/L) | 0.09 (0.05) | 0.1 | 0.1 (0.05) | 0.06 | −0.09 (0.07) | 0.17 | 0.01 (0.07) | 0.90 |
| −0.08 (0.06) | 0.20 | −0.01 (0.06) | 0.87 | 0.10 (0.06) | 0.08 | 0.02 (0.06) | 0.74 | |
| Large HDL (µmol/L) | −0.11 (0.06) | 0.08 | −0.05 (0.06) | 0.45 | 0.16 (0.06) | 0.05 (0.07) | 0.46 | |
| Medium HDL (µmol/L) | −0.15 (0.07) | −0.03 (0.06) | 0.66 | 0.004 (0.05) | 0.94 | −0.03 (0.05) | 0.62 | |
| Small HDL (µmol/L) | 0.1 (0.06) | 0.09 | 0.04 (0.06) | 0.52 | 0.04 (0.06) | 0.55 | 0.03 (0.06) | 0.59 |
| VLDL particle size (nm) | −0.18(0.06) | −0.03 (0.05) | 0.64 | 0.05 (0.07) | 0.51 | −0.001 (0.07) | 0.98 | |
| LDL particle size (nm) | −0.05 (0.05) | 0.39 | −0.04 (0.05) | 0.46 | 0.06 (0.07) | 0.41 | 0.01 (0.07) | 0.85 |
| HDL particle size (nm) | −0.15(0.06) | −0.10 (0.06) | 0.08 | 0.14 (0.07) | 0.06 (0.07) | 0.36 | ||
| Total cholesterol (mg/dl) | 0.05 (0.06) | 0.41 | 0.08 (0.05) | 0.13 | 0.06 (0.06) | 0.34 | 0.03 (0.07) | 0.63 |
| Triglyceride (mg/dl) | −0.07 (0.05) | 0.14 | 0.07 (0.05) | 0.11 | −0.15 (0.09) | 0.08 | −0.15 (0.09) | 0.11 |
| LDL–cholesterol (mg/dl) | 0.11 (0.06) | 0.10 (0.05) | 0.01 (0.07) | 0.90 | 0.02 (0.07) | 0.76 | ||
| Non–HDL–cholesterol (mg/dl) | 0.07 (0.06) | 0.22 | 0.09 (0.05) | 0.09 | −0.02 (0.07) | 0.75 | −0.001 (0.07) | 0.92 |
| HDL–cholesterol (mg/dl) | −0.07 (0.07) | 0.30 | −0.02 (0.06) | 0.72 | 0.18 (0.06) | 0.08 (0.06) | 0.18 | |
P values in bold if significant (<0.05).
Models were adjusted for DCCT randomization, albumin excretion rate, HbA1C, diabetes duration, body mass index, and current smoking at DCCT baseline (1983–89). The regression models were also adjusted for statin use (any time during the DCCT baseline to EDIC year 12), ultrasound devices, and image readers at EDIC year 1 and 6 respectively.
DCCT baseline lipoprotein profiles vs. internal carotid IMT-EDIC Years 1 and 6 (standardized linear regression coefficientsa).
| Variables | ||||||||
|---|---|---|---|---|---|---|---|---|
| Slope (SE) | Slope (SE) | Slope (SE) | Slope (SE) | |||||
| −0.01 (0.07) | 0.92 | −0.03 (0.07) | 0.67 | 0.01 (0.06) | 0.83 | 0.06 (0.07) | 0.35 | |
| Large VLDL and chylomicrons (nmol/L) | −0.04 (0.07) | 0.55 | −0.07 (0.07) | 0.33 | −0.003 (0.07) | 0.97 | 0.05 (0.07) | 0.50 |
| Medium VLDL (nmol/L) | 0.07 (0.07) | 0.28 | 0.02 (0.07) | 0.80 | 0.04 (0.07) | 0.57 | 0.01 (0.07) | 0.84 |
| Small VLDL (nmol/L) | −0.05 (0.07) | 0.51 | −0.04 (0.07) | 0.55 | 0.001 (0.06) | 0.99 | 0.06 (0.06) | 0.33 |
| 0.23 (0.07) | 0.14 (0.07) | 0.06 | 0.004 (0.06) | 0.95 | −0.02 (0.06) | 0.74 | ||
| IDL (nmol/L) | 0.09 (0.07) | 0.22 | 0.004 (0.07) | 0.96 | 0.08 (0.06) | 0.18 | 0.09 (0.06) | 0.13 |
| Large LDL (nmol/L) | 0.02 (0.07) | 0.75 | 0.03 (0.07) | 0.61 | −0.002 (0.06) | 0.97 | −0.04 (0.06) | 0.52 |
| Small LDL (nmol/L) | 0.14 (0.07) | 0.09 (0.07) | 0.21 | −0.03 (0.07) | 0.65 | −0.03 (0.07) | 0.65 | |
| 0.09 (0.08) | 0.26 | 0.07 (0.08) | 0.38 | −0.02 (0.05) | 0.67 | −0.09 (0.06) | 0.12 | |
| Large HDL (µmol/L) | 0.04 (0.08) | 0.63 | −0.07 (0.08) | 0.42 | −0.03 (0.06) | 0.62 | −0.03 (0.06) | 0.56 |
| Medium HDL (µmol/L) | 0.10 (0.08) | 0.23 | 0.02 (0.08) | 0.79 | −0.03 (0.05) | 0.52 | −0.06 (0.05) | 0.23 |
| Small HDL (µmol/L) | 0.20 (0.08) | 0.09 (0.08) | 0.26 | 0.001 (0.06) | 0.99 | −0.001 (0.06) | 0.99 | |
| VLDL particle size (nm) | −0.0001 (0.07) | 1.00 | −0.06 (0.07) | 0.44 | 0.03 (0.07) | 0.66 | 0.02 (0.07) | 0.75 |
| LDL particle size (nm) | −0.08 (0.07) | 0.25 | −0.03 (0.07) | 0.63 | 0.02 (0.07) | 0.75 | 0.02 (0.06) | 0.71 |
| HDL particle size (nm) | −0.13 (0.08) | 0.08 | 0.06 (0.07) | 0.35 | 0.07 (0.06) | 0.29 | −0.12 (0.08) | 0.11 |
| Total cholesterol (mg/dl) | 0.17 (0.07) | 0.13 (0.07) | 0.07 | 0.15 (0.06) | 0.05 (0.06) | 0.44 | ||
| Triglyceride (mg/dl) | 0.02 (0.06) | 0.76 | 0.04 (0.06) | 0.51 | 0.04 (0.09) | 0.64 | 0.06 (0.09) | 0.52 |
| LDL–cholesterol (mg/dl) | 0.17 (0.07) | 0.14 (0.07) | 0.12 (0.06) | 0.04 (0.06) | 0.51 | |||
| Non–HDL–cholesterol (mg/dl) | 0.16 (0.07) | 0.12 (0.07) | 0.09 | 0.12 (0.06) | 0.05 (0.07) | 0.45 | ||
| HDL–cholesterol (mg/dl) | 0.05 (0.08) | 0.57 | 0.04 (0.08) | 0.62 | 0.09 (0.06) | 0.12 | 0.01 (0.06) | 0.87 |
P values in bold if significant (<0.05).
Models were adjusted for DCCT randomization, albumin excretion rate, HbA1C, diabetes duration, body mass index, and current smoking at DCCT baseline (1983–89). The regression models were also adjusted for statin use (any time during the DCCT baseline to EDIC year 12), ultrasound devices, and image readers at EDIC year 1 and 6 respectively.
| Subject area | Biology |
|---|---|
| More specific subject area | Endocrinology, Lipid metabolism |
| Type of data | Tables |
| How data was acquired | NMR, Ultrasound reading |
| Data format | Analyzed |
| Experimental factors | EDIC Years 1 and 6 after intensive or conventional diabetes management in DCCT vs DCCT baseline |
| Experimental features | Lipoprotein subclasses and conventional lipids at DCCT baseline correlated with carotid IMT in follow-up years |
| Data source location | DCCT/EDIC centers (USA, Canada) |
| Data accessibility | Within the Data in Brief article |